Notably, KOR agonists are non-addictive [26,27], do not induce respiratory depression [28,29] or gastrointestinal side effects [30], and show less antinociceptive tolerance [19]. The gene discussed is OPRK1; the disease is Respiratory insufficiency due to muscle weakness.